Jul 21
|
Expanding Analyst Interest in ORYZON
|
Jun 26
|
ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference
|
Dec 4
|
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.
|